Youth Gender-Affirming Care Timeline.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Treatment seekers are referred via Aland health and medical services to hospitals in mainland Finland or Sweden. Start year of the arrangement not verified.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Proclaimed in force 7 January 2026: hormone prescribing to minors for gender dysphoria only under a ministerial order, which allows continuation of earlier treatment and new prescriptions at 16 and 17 with parental,…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Public paediatric and adult gender services, with the adult service taking people from 16. Start year not verified.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

The Health Minister saw no reason to change the Austrian legal position on gender-affirming treatment.

From 13 October 2026 Medi-Cal stopped paying for puberty blockers and surgery for gender transition for under-19s and for new hormone starts, keeping hormones for existing users until 12 April 2027 and then moving them…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

The Health Minister saw no reason to change the Austrian legal position on gender-affirming treatment.

Current law: trans people have a right to pharmacological treatment and to the surgical portfolio, mental-disorder diagnostic categories may not be used and diagnostic assessments of gender identity are banned.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Western Australian laws apply on the islands, as modified by ordinance; the year WA laws were first applied is not verified here.

Colorado Medicaid ended coverage of gender-affirming medication and surgery for under-18s from 13 October 2026 after the federal rule.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Delaware said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Preparations for the only NHS research route to puberty blockers were paused after MHRA raised new concerns; recruitment has not started.

From 10 March 2026 no new prescriptions of masculinising or feminising hormones are started through the NHS Children and Young People's Gender Service; existing 16 and 17 year old patients may continue after review.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Treatment takes place in Denmark and may be funded by the Faroese health system if approved by the Danish system. Start year of the arrangement not verified.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

HAS began work on national recommendations for minors; no recommendation is yet in force.

HAS began work on national recommendations for minors; no recommendation is yet in force.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

HAS began work on national recommendations for minors; no recommendation is yet in force.

Hawai'i said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Documents that doctors require psychologist and psychiatrist opinions establishing ICD-10 F64.00, that hormones need doctor-specific off-label permits from the national public health centre with fresh opinions, and that…

The statutory youth team allows a minimum of six to 12 months to get to know a client before deciding on interventions. 2026 is the year the page was read; the start of this rule was not verified.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Illinois said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

The HSE is developing a new model of care for adults and young people, expected in the fourth quarter of 2026; no finalised national model of care for minors exists.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Temporary statewide injunction against the medication bans in SB 63, sections 3(a)(2), 3(a)(3), 3(b)(2) and 3(b)(3); the surgery ban and funding provisions were not challenged and remain in force.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Amended another annex of Order No. KR DSM-203/2020 and treats the order as in force, which confirms the 2020 rules on sex change remain current; the sex change annex was not changed.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

States that gender identity disorders are classed in ICD-10 as mental and behavioural disorders and that the diagnosis is made by a psychiatrist or a doctors' council.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

The Health Minister saw no reason to change the Austrian legal position on gender-affirming treatment.

Maine said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

HAS began work on national recommendations for minors; no recommendation is yet in force.

Maryland said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

MassHealth made no change to gender-affirming care coverage after the federal rule and will cover any lost federal funding from the state Affirming Health Care Trust.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

HAS began work on national recommendations for minors; no recommendation is yet in force.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

Michigan Medicaid ended coverage of gender-affirming care for under-18s after the federal rule.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

The Missouri Supreme Court unanimously upheld SB 49.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Health Council found somatic treatment of young people fits the health law framework and advised revisions and monitoring; no restriction adopted.

Suspended the effects of Decree 62/2025 nationwide until final judgment, restoring the original article 11 for minors.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

Current youth referral routes to child and youth teams and paediatricians as read for the audit. Start year not verified.

From 1 January 2026 bars puberty blockers and cross-sex hormones for gender transition for under-18s, letting treatment begun before that date continue; HB 712 (2024) had already barred chest surgery for minors.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.

From 13 October 2026 state Medicaid plans may not pay for puberty blockers, cross-sex hormones or surgery for gender transition for under-18s (under-19s in separate CHIP), with a six-month taper for current hormone…

New Mexico said its Medicaid programme would continue covering gender-affirming care for young people with state-only funds after the federal rule took effect on 13 October 2026.

A federal court vacated the December 2025 HHS declaration that youth gender-affirming care falls below professional standards, finding HHS lacked authority to override state standards of care.